JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB280120

Human CDKN1C (p57 Kip2) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

CDKN1C KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 217 bp deletion in exon 1.

View Alternative Names

BWCR, BWS, Beckwith Wiedemann syndrome, CDKI, CDKN 1C, CDN1C_HUMAN, Cyclin-dependent kinase inhibitor 1C, Cyclin-dependent kinase inhibitor p57, KIP 2, WBS, p57, p57 Kip 2

2 Images
Western blot - Human CDKN1C (p57 Kip2) knockout HeLa cell lysate (AB280120)
  • WB

Lab

Western blot - Human CDKN1C (p57 Kip2) knockout HeLa cell lysate (AB280120)

Lane 1 : Wild-type HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277359 cell lysate 20 μg
Lane 2 : Wild-type HeLa Treated Dexamethasone (50 nM, 16 h) ab287335 cell lysate 20 μg
Lane 3 : CDKN1C knockout HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277299 cell lysate 20 μg
Lane 4 : CDKN1C knockout HeLa Treated Dexamethasone (50 nM, 16 h) ab281877 cell lysate 20 μg
Lane 5 : MCF7 cell lysate 20 μg
Lane 6 : SH-SY5Y cell lysate 20 μg
False colour image of Western blot : Anti-p57 Kip2 antibody [EP2516] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab119989 was shown to bind specifically to p57 Kip2. A band was observed at 50 kDa in wild-type HeLa cell lysates with no signal observed at this size in CDKN1C knockout cell line ab280061 (knockout cell lysate ab280120). To generate this image, wild-type and CDKN1C knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) at 1/20000 dilution.

All lanes:

Western blot - Anti-p57 Kip2 antibody [EP2516] (<a href='/en-us/products/primary-antibodies/p57-kip2-antibody-ep2516-ab119989'>ab119989</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277359 cell lysate at 20 µg

Lane 2:

Wild-type HeLa Treated Dexamethasone (50 nM, 16 h) ab287335 cell lysate at 20 µg

Lane 2:

Western blot - Human CDKN1C (p57 Kip2) knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-cdkn1c-p57-kip2-knockout-hela-cell-line-ab280061'>ab280061</a>)

Lane 3:

CDKN1C knockout HeLa Vehicle Control Dexamethasone (0 nM, 16 h) ab277299 cell lysate at 20 µg

Lane 4:

CDKN1C knockout HeLa Treated Dexamethasone (50 nM, 16 h) ab281877 cell lysate at 20 µg

Lane 5:

MCF7 cell lysate at 20 µg

Lane 6:

SH-SY5Y cell lysate at 20 µg

Predicted band size: 32 kDa

Observed band size: 50 kDa

false

Sanger Sequencing - Human CDKN1C (p57 Kip2) knockout HeLa cell lysate (AB280120)
  • Sanger seq

Lab

Sanger Sequencing - Human CDKN1C (p57 Kip2) knockout HeLa cell lysate (AB280120)

217 bp Deletion in Exon 1

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 217 bp deletion in exon 1

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab280120-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human CDKN1C knockout HeLa cell lysate", "number":"AB280120-CMP01", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB280120-CMP02", "productcode":"" } ] } } }

Properties and storage information

Gene name
CDKN1C
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The protein p57^Kip2 also known as CDKN1C plays an important role as a cyclin-dependent kinase inhibitor aligning closely with proteins like p21 and p27. It weighs approximately 57 kiloDaltons. P57^Kip2's expression occurs in various tissues including the placenta muscle brain and kidney. This widespread expression suggests a multitiered function in different tissues. Researchers use p57 immunostain techniques to confirm its presence in tissues.
Biological function summary

P57^Kip2 acts as a regulator of cell cycle progression. It binds directly to cyclin-CDK complexes stopping cell cycle transition from G1 to S phase. This action prevents unregulated cell division and contributes to cellular differentiation. p57^Kip2 forms part of larger protein complexes further influencing various cellular processes. Its activity is important for embryonic development where it controls cell proliferation rates.

Pathways

P57^Kip2 integrates into pathways controlling cell cycle checkpoints and apoptosis. It interacts with proteins like cyclin D and E and the retinoblastoma protein (Rb) within the cell cycle regulation pathway. Additionally its presence in growth signaling pathways intersects with TGF-beta signaling. These pathways hold significant influence over development and cellular responses to DNA damage.

Abnormal expression of p57^Kip2 connects with cancers and growth disorders. Loss of function or downregulation often links to overgrowth syndromes like Beckwith-Wiedemann syndrome. Conversely reduced expression levels associate with cancer proliferation particularly in cases such as Wilms' tumor. This association intertwines with mutations in genes like IGF2 and H19 which are critical in these conditions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com